Overview

Tolerability and Activity of Brivaracetam (BRV) in Patients With Diffuse Gliomas

Status:
Not yet recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether the study medication, brivaracetam, is tolerable and safe for patients with brain tumors.
Phase:
Early Phase 1
Details
Lead Sponsor:
University of Rochester
Treatments:
Brivaracetam